share_log

HC Wainwright & Co. Reiterates Buy on Lyra Therapeutics, Maintains $12 Price Target

Benzinga ·  Oct 2, 2023 07:03

HC Wainwright & Co. analyst Matthew Caufield reiterates Lyra Therapeutics (NASDAQ:LYRA) with a Buy and maintains $12 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment